APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fatty Liver Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Fatty Liver Drugs Market Analysis and Forecast 2026-2032

30 December 2025194 pages

Choose your research edition.

Industry ResearchFatty Liver Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Fatty Liver Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Fatty Liver Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fatty Liver Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Fatty Liver Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Fatty Liver Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Fatty Liver Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Fatty Liver Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Fatty Liver Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Fatty Liver Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Fatty Liver Drugs include Allergan, Astra Zenca, Conatus, Gilead Sciences, Hepion Pharmaceuticals, Immuron, Intercept Pharmaceuticals, Madrigal and Merk, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Fatty Liver Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Fatty Liver Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Fatty Liver Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Fatty Liver Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Fatty Liver Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Fatty Liver Drugs revenue, projected growth trends, production technology, application and end-user industry.

Fatty Liver Drugs Segment by Company

Allergan

Astra Zenca

Conatus

Gilead Sciences

Hepion Pharmaceuticals

Immuron

Intercept Pharmaceuticals

Madrigal

Merk

Pfizer

Novartis

Takeda

Fatty Liver Drugs Segment by Type

ALD

NAFLD

Fatty Liver Drugs Segment by Application

Hospital

Clinic

Others

Fatty Liver Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fatty Liver Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fatty Liver Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fatty Liver Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Fatty Liver Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Fatty Liver Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Fatty Liver Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Fatty Liver Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. ALD Major Player Table 3. NAFLD Major Player Table 4. Global Fatty Liver Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Others Major Player Table 8. Fatty Liver Drugs Industry Trends Table 9. Fatty Liver Drugs Industry Drivers Table 10. Fatty Liver Drugs Industry Opportunities and Challenges Table 11. Fatty Liver Drugs Industry Restraints Table 12. Global Fatty Liver Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Fatty Liver Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Fatty Liver Drugs Market Share by Region (2021-2026) Table 15. Global Fatty Liver Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Fatty Liver Drugs Market Share by Region (2027-2032) Table 17. Global Fatty Liver Drugs Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Fatty Liver Drugs Revenue Market Share by Players (2021-2026) Table 19. Global Fatty Liver Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Fatty Liver Drugs Key Players Headquarters & Area Served Table 21. Global Fatty Liver Drugs Players, Product Type & Application Table 22. Global Fatty Liver Drugs Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Fatty Liver Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Fatty Liver Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Fatty Liver Drugs Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Fatty Liver Drugs Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Fatty Liver Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Fatty Liver Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Fatty Liver Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Fatty Liver Drugs Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Fatty Liver Drugs Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Fatty Liver Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Fatty Liver Drugs Revenue Market Share by Application (2027-2032) Table 35. Allergan Company Information Table 36. Allergan Business Overview Table 37. Allergan Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Allergan Fatty Liver Drugs Product Portfolio Table 39. Allergan Recent Development Table 40. Astra Zenca Company Information Table 41. Astra Zenca Business Overview Table 42. Astra Zenca Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Astra Zenca Fatty Liver Drugs Product Portfolio Table 44. Astra Zenca Recent Development Table 45. Conatus Company Information Table 46. Conatus Business Overview Table 47. Conatus Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Conatus Fatty Liver Drugs Product Portfolio Table 49. Conatus Recent Development Table 50. Gilead Sciences Company Information Table 51. Gilead Sciences Business Overview Table 52. Gilead Sciences Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Gilead Sciences Fatty Liver Drugs Product Portfolio Table 54. Gilead Sciences Recent Development Table 55. Hepion Pharmaceuticals Company Information Table 56. Hepion Pharmaceuticals Business Overview Table 57. Hepion Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Hepion Pharmaceuticals Fatty Liver Drugs Product Portfolio Table 59. Hepion Pharmaceuticals Recent Development Table 60. Immuron Company Information Table 61. Immuron Business Overview Table 62. Immuron Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Immuron Fatty Liver Drugs Product Portfolio Table 64. Immuron Recent Development Table 65. Intercept Pharmaceuticals Company Information Table 66. Intercept Pharmaceuticals Business Overview Table 67. Intercept Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Intercept Pharmaceuticals Fatty Liver Drugs Product Portfolio Table 69. Intercept Pharmaceuticals Recent Development Table 70. Madrigal Company Information Table 71. Madrigal Business Overview Table 72. Madrigal Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Madrigal Fatty Liver Drugs Product Portfolio Table 74. Madrigal Recent Development Table 75. Merk Company Information Table 76. Merk Business Overview Table 77. Merk Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Merk Fatty Liver Drugs Product Portfolio Table 79. Merk Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Pfizer Fatty Liver Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Fatty Liver Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Novartis Fatty Liver Drugs Product Portfolio Table 89. Novartis Recent Development Table 90. Takeda Company Information Table 91. Takeda Business Overview Table 92. Takeda Fatty Liver Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Takeda Fatty Liver Drugs Product Portfolio Table 94. Takeda Recent Development Table 95. North America Fatty Liver Drugs Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Fatty Liver Drugs Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Fatty Liver Drugs Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Fatty Liver Drugs Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Fatty Liver Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Fatty Liver Drugs Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Fatty Liver Drugs Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe Fatty Liver Drugs Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe Fatty Liver Drugs Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe Fatty Liver Drugs Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe Fatty Liver Drugs Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe Fatty Liver Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Fatty Liver Drugs Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe Fatty Liver Drugs Revenue by Country (US$ Million) & (2027-2032) Table 109. China Fatty Liver Drugs Revenue by Type (2021-2026) & (US$ Million) Table 110. China Fatty Liver Drugs Revenue by Type (2027-2032) & (US$ Million) Table 111. China Fatty Liver Drugs Revenue by Application (2021-2026) & (US$ Million) Table 112. China Fatty Liver Drugs Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Fatty Liver Drugs Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia Fatty Liver Drugs Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia Fatty Liver Drugs Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia Fatty Liver Drugs Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Fatty Liver Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Fatty Liver Drugs Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia Fatty Liver Drugs Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA Fatty Liver Drugs Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA Fatty Liver Drugs Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA Fatty Liver Drugs Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA Fatty Liver Drugs Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA Fatty Liver Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA Fatty Liver Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA Fatty Liver Drugs Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Fatty Liver Drugs Image Figure 2. Global Fatty Liver Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fatty Liver Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. ALD Image Figure 5. NAFLD Image Figure 6. Global Fatty Liver Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Fatty Liver Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Fatty Liver Drugs Market Size (US$ Million) & (2021-2032) Figure 12. Global Fatty Liver Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Fatty Liver Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Fatty Liver Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Fatty Liver Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Fatty Liver Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Fatty Liver Drugs Revenue Market Share by Type (2021-2032) Figure 19. Global Fatty Liver Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Fatty Liver Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Fatty Liver Drugs Revenue Market Share by Application (2021-2032) Figure 22. North America Fatty Liver Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Fatty Liver Drugs Revenue Share by Type (2021-2032) Figure 24. North America Fatty Liver Drugs Revenue Share by Application (2021-2032) Figure 25. North America Fatty Liver Drugs Revenue Share by Country (2021-2032) Figure 26. United States Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Fatty Liver Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Fatty Liver Drugs Revenue Share by Type (2021-2032) Figure 31. Europe Fatty Liver Drugs Revenue Share by Application (2021-2032) Figure 32. Europe Fatty Liver Drugs Revenue Share by Country (2021-2032) Figure 33. Germany Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Fatty Liver Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Fatty Liver Drugs Revenue Share by Type (2021-2032) Figure 43. China Fatty Liver Drugs Revenue Share by Application (2021-2032) Figure 44. Asia Fatty Liver Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Fatty Liver Drugs Revenue Share by Type (2021-2032) Figure 46. Asia Fatty Liver Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Fatty Liver Drugs Revenue Share by Region (2021-2032) Figure 48. Japan Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Fatty Liver Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Fatty Liver Drugs Revenue Share by Type (2021-2032) Figure 56. SAMEA Fatty Liver Drugs Revenue Share by Application (2021-2032) Figure 57. SAMEA Fatty Liver Drugs Revenue Share by Country (2021-2032) Figure 58. Brazil Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Fatty Liver Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • ALD
  • NAFLD
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Allergan
  • Astra Zenca
  • Conatus
  • Gilead Sciences
  • Hepion Pharmaceuticals
  • Immuron
  • Intercept Pharmaceuticals
  • Madrigal
  • Merk
  • Pfizer
  • Novartis
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Fatty Liver Drugs Market by Type
  3. 1.2.1 Global Fatty Liver Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 ALD
  5. 1.2.3 NAFLD
  6. 1.3 Fatty Liver Drugs Market by Application
  7. 1.3.1 Global Fatty Liver Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Fatty Liver Drugs Market Dynamics
  1. 2.1 Fatty Liver Drugs Industry Trends
  2. 2.2 Fatty Liver Drugs Industry Drivers
  3. 2.3 Fatty Liver Drugs Industry Opportunities and Challenges
  4. 2.4 Fatty Liver Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Fatty Liver Drugs Market Perspective (2021-2032)
  2. 3.2 Global Fatty Liver Drugs Growth Trends by Region
  3. 3.2.1 Global Fatty Liver Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Fatty Liver Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Fatty Liver Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Fatty Liver Drugs Revenue by Players
  2. 4.1.1 Global Fatty Liver Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Fatty Liver Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Fatty Liver Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Fatty Liver Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Fatty Liver Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Fatty Liver Drugs Players, Product Type & Application
  8. 4.5 Global Fatty Liver Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Fatty Liver Drugs Market CR5 and HHI
  11. 4.6.3 2025 Fatty Liver Drugs Tier 1, Tier 2, and Tier 3
5 Fatty Liver Drugs Market Size by Type
  1. 5.1 Global Fatty Liver Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Fatty Liver Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Fatty Liver Drugs Revenue Market Share by Type (2021-2032)
6 Fatty Liver Drugs Market Size by Application
  1. 6.1 Global Fatty Liver Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Fatty Liver Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Fatty Liver Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Fatty Liver Drugs Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 Astra Zenca
  8. 7.2.1 Astra Zenca Company Information
  9. 7.2.2 Astra Zenca Business Overview
  10. 7.2.3 Astra Zenca Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Astra Zenca Fatty Liver Drugs Product Portfolio
  12. 7.2.5 Astra Zenca Recent Developments
  13. 7.3 Conatus
  14. 7.3.1 Conatus Company Information
  15. 7.3.2 Conatus Business Overview
  16. 7.3.3 Conatus Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Conatus Fatty Liver Drugs Product Portfolio
  18. 7.3.5 Conatus Recent Developments
  19. 7.4 Gilead Sciences
  20. 7.4.1 Gilead Sciences Company Information
  21. 7.4.2 Gilead Sciences Business Overview
  22. 7.4.3 Gilead Sciences Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Gilead Sciences Fatty Liver Drugs Product Portfolio
  24. 7.4.5 Gilead Sciences Recent Developments
  25. 7.5 Hepion Pharmaceuticals
  26. 7.5.1 Hepion Pharmaceuticals Company Information
  27. 7.5.2 Hepion Pharmaceuticals Business Overview
  28. 7.5.3 Hepion Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Hepion Pharmaceuticals Fatty Liver Drugs Product Portfolio
  30. 7.5.5 Hepion Pharmaceuticals Recent Developments
  31. 7.6 Immuron
  32. 7.6.1 Immuron Company Information
  33. 7.6.2 Immuron Business Overview
  34. 7.6.3 Immuron Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Immuron Fatty Liver Drugs Product Portfolio
  36. 7.6.5 Immuron Recent Developments
  37. 7.7 Intercept Pharmaceuticals
  38. 7.7.1 Intercept Pharmaceuticals Company Information
  39. 7.7.2 Intercept Pharmaceuticals Business Overview
  40. 7.7.3 Intercept Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Intercept Pharmaceuticals Fatty Liver Drugs Product Portfolio
  42. 7.7.5 Intercept Pharmaceuticals Recent Developments
  43. 7.8 Madrigal
  44. 7.8.1 Madrigal Company Information
  45. 7.8.2 Madrigal Business Overview
  46. 7.8.3 Madrigal Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Madrigal Fatty Liver Drugs Product Portfolio
  48. 7.8.5 Madrigal Recent Developments
  49. 7.9 Merk
  50. 7.9.1 Merk Company Information
  51. 7.9.2 Merk Business Overview
  52. 7.9.3 Merk Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merk Fatty Liver Drugs Product Portfolio
  54. 7.9.5 Merk Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Fatty Liver Drugs Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Novartis
  62. 7.11.1 Novartis Company Information
  63. 7.11.2 Novartis Business Overview
  64. 7.11.3 Novartis Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novartis Fatty Liver Drugs Product Portfolio
  66. 7.11.5 Novartis Recent Developments
  67. 7.12 Takeda
  68. 7.12.1 Takeda Company Information
  69. 7.12.2 Takeda Business Overview
  70. 7.12.3 Takeda Fatty Liver Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Takeda Fatty Liver Drugs Product Portfolio
  72. 7.12.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Fatty Liver Drugs Revenue (2021-2032)
  2. 8.2 North America Fatty Liver Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Fatty Liver Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Fatty Liver Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Fatty Liver Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Fatty Liver Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Fatty Liver Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Fatty Liver Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Fatty Liver Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Fatty Liver Drugs Revenue by Country
  11. 8.6.1 North America Fatty Liver Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Fatty Liver Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Fatty Liver Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Fatty Liver Drugs Revenue (2021-2032)
  2. 9.2 Europe Fatty Liver Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Fatty Liver Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Fatty Liver Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Fatty Liver Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Fatty Liver Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Fatty Liver Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Fatty Liver Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Fatty Liver Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Fatty Liver Drugs Revenue by Country
  11. 9.6.1 Europe Fatty Liver Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Fatty Liver Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Fatty Liver Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Fatty Liver Drugs Revenue (2021-2032)
  2. 10.2 China Fatty Liver Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Fatty Liver Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Fatty Liver Drugs Revenue by Type (2027-2032)
  5. 10.3 China Fatty Liver Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Fatty Liver Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Fatty Liver Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Fatty Liver Drugs Revenue by Application (2027-2032)
  9. 10.5 China Fatty Liver Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Fatty Liver Drugs Revenue (2021-2032)
  2. 11.2 Asia Fatty Liver Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Fatty Liver Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Fatty Liver Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Fatty Liver Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Fatty Liver Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Fatty Liver Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Fatty Liver Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Fatty Liver Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Fatty Liver Drugs Revenue by Country
  11. 11.6.1 Asia Fatty Liver Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Fatty Liver Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Fatty Liver Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Fatty Liver Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Fatty Liver Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Fatty Liver Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Fatty Liver Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Fatty Liver Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Fatty Liver Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Fatty Liver Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Fatty Liver Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Fatty Liver Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Fatty Liver Drugs Revenue by Country
  11. 12.6.1 SAMEA Fatty Liver Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Fatty Liver Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Fatty Liver Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst